Fig. 3: Comparison of antibody titers between heterologous ChAdOx1/MVC-COV1901 (n = 50) and homologous ChAdOx1/ChAdOx1 (n = 50) groups prior to and after booster vaccination.
a Neutralizing antibody titers measured by ELISA-based method. The data from 15 human convalescent serum samples collected at day 28 ± 3 after diagnosis is shown for comparison (grey bar). The values in international units per milliliter (IU/mL) are provided. Data are presented as geometric mean ±95% confidence intervals. The significance between two groups was determined using t test (two-tailed). Comparisons of antibody titers, Day 0, P = 0.7900; Day 10 ± 3, P < 0.0010; Day 28 ± 3, P < 0.0010. b Neutralizing antibody titers against wild-type Wuhan-1 and Delta variant measured by plaque reduction neutralization assay for day 28 ± 3 serum. The half-maximal neutralization titer (NT50) values are provided. Data are presented as geometric mean ±95% confidence intervals. The significance between two groups was determined using t test (two-tailed). Comparisons of antibody titers, Wuhan strain, P < 0.0010; Delta strain, P < 0.0010. c Binding-antibody titers in ELISA Unit (EU) against spike S1 protein and receptor-binding domain (RBD). Comparisons of anti-S1 titers, Day 0, P = 0.5260; Day 10 ± 3, P < 0.0010; Day 28 ± 3, P < 0.0010. Comparisons of anti-RBD titers, Day 0, P = 0.4850; Day 10 ± 3, P = 0.0020; Day 28 ± 3, P < 0.0010. Data are presented as geometric mean ±95% confidence intervals. The significance between two groups was determined using t test (two-tailed). **P < 0.01, ***P < 0.001, NS not significant. Source data are provided as a Source Data file.
